Seizure Burden in IDH-Mutant Glioma: Impact on Daily Function and Quality of Life

Diffuse gliomas harboring IDH mutations are often diagnosed in younger adults and are characterized by a prolonged disease course that can significantly affect quality of life. Among the most common and impactful symptoms are seizures, which frequently serve as the initial presentation and remain a persistent challenge throughout the disease trajectory, even in patients with otherwise stable tumor burden.

At the 2026 AAN Annual Meeting in Chicago, Katherine B. Peters, MD, PhD, neuro-oncologist at Duke Health and professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center, joined NeurologyLive® to discuss emerging insights from the phase 3 INDIGO trial evaluating vorasidenib in IDH-mutant diffuse glioma. The conversation explores both the biological underpinnings of seizure activity and the broader clinical implications of targeted IDH inhibition, particularly in the context of patient-centered outcomes.

In this opening episode, Peters focuses on the clinical burden of seizures in grade 2 IDH-mutant glioma. She discusses how seizure activity affects patients’ ability to work, drive, and maintain independence, particularly given the younger age at diagnosis, and underscores the importance of managing seizures alongside tumor-directed therapy to optimize long-term quality of life.